# US 2017/0281679 A1 · Method for preparing universal plasma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281679 A1
- Document ID: US20170281679A1
- Status: Published application
- Kind: A1
- Application number: 15/512,185
- Filed: 2015-10-09
- Published: 2017-10-05
- Earliest claimed: 2014-10-09
- Assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
- Applicants: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
- Inventors: Abdessatar Chtourou
- Web page: https://patentgrep.com/patent/US20170281679A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01D 61/145: {Ultrafiltration}
- B01D 2311/2626: Absorption or adsorption
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A process for the preparation of a universal plasma, comprising the following steps:
a) mixing non-universal unit plasmas obtained from a sample from donor individuals,
b) simultaneous removal of anti-A and anti-B antibodies present in the plasma by immunoaffinity chromatography or by in batch depletion, and
c) optionally, lyophilization or atomization of the universal plasma originating from step b).

### Claim 18 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, wherein step a) is carried out with no prior selection of donors.

### Claim 19 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, wherein step b) is carried out by immunoaffinity chromatography or by in batch depletion on a support grafted with oligosaccharide groups antigenically similar to blood groups A and B.

### Claim 20 (depends on 19)

A process for the preparation of a universal plasma according to claim 19, wherein the oligosaccharide groups are trisaccharides corresponding to the epitopes of blood groups A and B.

### Claim 21 (depends on 20)

A process for the preparation of a universal plasma according to claim 20, wherein trisaccharides corresponding to the blood group A epitope have the structure N-acetylgalactosamine (GalNAc)-Galactose (Gal)-Fucose (Fuc), and trisaccharides corresponding to the blood group B epitope have the structure Galactose-Galactose-Fucose.

### Claim 22 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, wherein the donor individuals belong to a blood group selected from blood group A, blood group B, blood group AB, and/or blood group O.

### Claim 23 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, wherein the donor individuals belong to blood group A, blood group B, blood group AB, and blood group O.

### Claim 24 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, wherein the universal plasma originating from step b) has an anti-A antibody content and an anti-B antibody content in the universal plasma such that the result of the Coombs test is negative at a 1/64 dilution measured according to the method described in chapter 2.6.20 of the European Pharmacopoeia 07/2011.

### Claim 25 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, further comprising a biological safety step.

### Claim 26 (depends on 25)

A process for the preparation of a universal plasma according to claim 25, wherein the biological safety step is carried out by viral inactivation by a solvent/detergent, preferably using a dialyzable or filterable solvent/detergent.

### Claim 27 (depends on 17)

A process for the preparation of a universal plasma according to claim 17, further comprising an ultrafiltration step.

### Claim 28 (depends on 27)

A process for the preparation of a universal plasma according to claim 27, wherein the ultrafiltration step is combined with a dialysis step.

### Claim 29 (depends on 17)

An universal plasma obtained by a process according to claim 17.

### Claim 30

An universal plasma wherein the anti-A antibody content and the anti-B antibody content are in accordance with a negative result in the Coombs test at a 1/64 dilution measured according to the method described in chapter 2.6.20 of the European Pharmacopoeia 07/2011:20620.

### Claim 31 (depends on 30)

The universal plasma according to claim 30, wherein the universal plasma is obtained from donor individuals belonging to blood groups A, B, AB, and O.

### Claim 32 (depends on 29)

A method for treating severe haemorrhages, traumatic or spontaneous haemorraghes under oral anticoagulant, severe vitamin K deficiency, or thrombotic thrombocytopaenic purpura, comprising administering to a person in need thereof the universal plasma of claim 29.
